CN111032082B - Her2阳性癌症的治疗 - Google Patents

Her2阳性癌症的治疗 Download PDF

Info

Publication number
CN111032082B
CN111032082B CN201880043831.3A CN201880043831A CN111032082B CN 111032082 B CN111032082 B CN 111032082B CN 201880043831 A CN201880043831 A CN 201880043831A CN 111032082 B CN111032082 B CN 111032082B
Authority
CN
China
Prior art keywords
cancer
trastuzumab
tocatinib
subject
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880043831.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN111032082A (zh
Inventor
S·彼德森
L·沃克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of CN111032082A publication Critical patent/CN111032082A/zh
Application granted granted Critical
Publication of CN111032082B publication Critical patent/CN111032082B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880043831.3A 2017-04-28 2018-04-27 Her2阳性癌症的治疗 Active CN111032082B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491872P 2017-04-28 2017-04-28
US62/491,872 2017-04-28
PCT/US2018/029899 WO2018201016A1 (en) 2017-04-28 2018-04-27 Treatment of her2 positive cancers

Publications (2)

Publication Number Publication Date
CN111032082A CN111032082A (zh) 2020-04-17
CN111032082B true CN111032082B (zh) 2025-01-07

Family

ID=62165692

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880043831.3A Active CN111032082B (zh) 2017-04-28 2018-04-27 Her2阳性癌症的治疗

Country Status (13)

Country Link
US (3) US11207324B2 (enExample)
EP (1) EP3615067A1 (enExample)
JP (2) JP7328151B2 (enExample)
KR (1) KR102845148B1 (enExample)
CN (1) CN111032082B (enExample)
AU (2) AU2018258663B2 (enExample)
BR (1) BR112019022280A2 (enExample)
CA (1) CA3060407A1 (enExample)
EA (1) EA201992573A1 (enExample)
MA (1) MA49059A (enExample)
SG (1) SG11201909676WA (enExample)
WO (1) WO2018201016A1 (enExample)
ZA (1) ZA201907225B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032082B (zh) * 2017-04-28 2025-01-07 西雅图基因公司 Her2阳性癌症的治疗
TW202042820A (zh) * 2019-01-28 2020-12-01 美商西雅圖遺傳學股份有限公司 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法
WO2020251556A1 (en) * 2019-06-11 2020-12-17 Io Therapeutics, Inc. Use of an rxr agonist in treating her2+ cancers
KR20220086627A (ko) * 2019-10-21 2022-06-23 시아겐 인크. 카페시타빈 및 트라스투주맙과 조합으로 투카티닙을 사용하여 her2 양성 유방암을 치료하는 방법
US20220387618A1 (en) * 2019-11-15 2022-12-08 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
IL298538A (en) * 2020-05-29 2023-01-01 Seagen Inc Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy
WO2022026510A1 (en) * 2020-07-29 2022-02-03 Seagen Inc. Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist
US20230372342A1 (en) * 2020-09-28 2023-11-23 Seagen Inc. Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
US11526994B1 (en) * 2021-09-10 2022-12-13 Neosoma, Inc. Labeling, visualization, and volumetric quantification of high-grade brain glioma from MRI images
WO2024183622A1 (zh) * 2023-03-03 2024-09-12 盛禾(中国)生物制药有限公司 一种抗her2抗体在制备治疗癌症的药物中的用途
WO2025132522A1 (en) 2023-12-20 2025-06-26 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
CA2129514A1 (en) 1992-03-12 1993-09-16 M. Amin Khan Controlled released acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
JP4828421B2 (ja) 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
US20100063074A1 (en) 2004-06-03 2010-03-11 Berger Mark S Cancer Treatment Method
DK1971601T3 (da) 2005-11-15 2010-02-08 Array Biopharma Inc N4-phenyl-quinazolin-4-aminderivater og beslægtede forbindelser som ERBB Type 1-receptortyrosinkinase-inhibitorer til behandling af hyperproliferative sygdomme
WO2009042618A1 (en) 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
MY166445A (en) 2008-03-18 2018-06-27 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents,and methods of use
NO2719708T3 (enExample) * 2009-11-13 2018-03-24
SG194609A1 (en) * 2011-05-19 2013-12-30 Lab Corp America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
WO2013056108A2 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Solid dispersion
EP2766363A1 (en) 2011-10-14 2014-08-20 Array Biopharma, Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions containing them
KR102490961B1 (ko) 2012-03-23 2023-01-19 어레이 바이오파마 인크. 뇌암의 치료
WO2016011328A1 (en) * 2014-07-17 2016-01-21 Baker Cheryl Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
US10702527B2 (en) * 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CN109952306A (zh) * 2016-04-19 2019-06-28 加利福尼亚大学董事会 ErbB抑制剂及其用途
CN111032082B (zh) 2017-04-28 2025-01-07 西雅图基因公司 Her2阳性癌症的治疗
US20210239702A1 (en) 2018-06-14 2021-08-05 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies
TW202042820A (zh) 2019-01-28 2020-12-01 美商西雅圖遺傳學股份有限公司 以妥卡替尼（Ｔｕｃａｔｉｎｉｂ）治療乳癌之方法
KR20220086627A (ko) 2019-10-21 2022-06-23 시아겐 인크. 카페시타빈 및 트라스투주맙과 조합으로 투카티닙을 사용하여 her2 양성 유방암을 치료하는 방법
US20220387618A1 (en) 2019-11-15 2022-12-08 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
MX2022011160A (es) 2020-03-11 2022-10-18 Seagen Inc Metodos de tratar canceres mutantes de her2 con tucatinib.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Abstract P4-21-01: Efficacy results of a phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases (mets);E Hamilton等;《Cancer Res》;20170215;第77卷(第4_Supplement期);第1-3页摘要部分 *
抗体药物偶联物阿多曲妥珠单抗依酯研究进展;李静等;《国际药学研究杂志》;20160830;第43卷(第04期);第665-668页第3部分 *

Also Published As

Publication number Publication date
MA49059A (fr) 2021-03-24
JP2020517696A (ja) 2020-06-18
KR102845148B1 (ko) 2025-08-20
SG11201909676WA (en) 2019-11-28
US11666572B2 (en) 2023-06-06
CA3060407A1 (en) 2018-11-01
US20200188401A1 (en) 2020-06-18
BR112019022280A2 (pt) 2020-05-19
AU2018258663A1 (en) 2019-11-14
ZA201907225B (en) 2023-11-29
AU2022241509A1 (en) 2022-10-27
US12048698B2 (en) 2024-07-30
WO2018201016A1 (en) 2018-11-01
US20220168303A1 (en) 2022-06-02
JP2023145689A (ja) 2023-10-11
EA201992573A1 (ru) 2020-04-06
US20230390290A1 (en) 2023-12-07
AU2022241509B2 (en) 2025-02-20
JP7328151B2 (ja) 2023-08-16
EP3615067A1 (en) 2020-03-04
US11207324B2 (en) 2021-12-28
AU2018258663B2 (en) 2022-08-04
CN111032082A (zh) 2020-04-17
KR20200014298A (ko) 2020-02-10

Similar Documents

Publication Publication Date Title
CN111032082B (zh) Her2阳性癌症的治疗
Krishnan et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177
US20230310455A1 (en) Combination therapies for treatment of her2 cancer
CN114945369A (zh) 图卡替尼与抗her2抗体-药物缀合物联合治疗her2阳性乳腺癌的方法
AU2010236818B2 (en) Combination therapy using an anti-EGFR agent(s) and IGF-1R specific inhibitors
WO2021190637A1 (en) Combination of anti-her2 antibody and cdk inhibitior for tumor treatment
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
HK40076724A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab
EA044960B1 (ru) Лечение her2-положительных злокачественных новообразований
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant